The United States Department of Health and Human Services (HHS) has announced the cancellation of contracts and funding for several vaccine projects aimed at combating respiratory viruses, including COVID-19 and influenza. This decision affects 22 projects worth US$500 million (approximately AU$770 million) that utilise mRNA technology, a key component in the COVID-19 vaccines produced by companies like Pfizer and Moderna.
Robert F. Kennedy Jr, a long-time critic of vaccines, proclaimed the termination of these projects, aligning with his ongoing scepticism towards vaccinations. He has previously rolled back recommendations for COVID-19 shots, dismissed the panel responsible for vaccine advice, and has yet to advocate strongly for vaccination amid a measles outbreak.
Kennedy, during a video statement, expressed criticism towards mRNA vaccines and indicated that the HHS would be redirecting efforts towards “safer, broader vaccine strategies”, such as whole-virus vaccines. This approach aims to ensure resilience against viral mutations rather than relying solely on mRNA technology, which some experts argue has been crucial in managing previous pandemics.
In response to the changes, experts in infectious diseases have voiced their concern. Mike Osterholm from the University of Minnesota described the decision as one of the most perilous in his 50-year career. Dr Paul Offit, an authority on vaccines, highlighted the effectiveness of mRNA in saving lives during the COVID-19 pandemic and warned that future outbreaks could be challenging to contain without this technology.
Furthermore, while Kennedy has proposed a “universal vaccine” that aims to replicate “natural immunity”, concerns remain about the implications of moving away from mRNA, especially as the threat of potential pandemics like bird flu persists. HHS rebutted that this decision does not impact ongoing use of mRNA technology elsewhere within the department, where it is being utilised for approved COVID-19 and RSV vaccinations.
The abandonment of these projects marks a notable shift in America’s vaccine development strategy, reflecting the current administration’s desire to explore alternative solutions. In previous statements, Kennedy has affirmed support for safe and effective vaccines for all Americans who wish to receive them, yet he maintains that the future focus will be on developing vaccines that provide broader immunity against a range of viruses. The cancellation of mRNA projects signifies a contentious pivot in the ongoing battle against respiratory infections.